Global Blood Therapeutics, Inc.
South San Francisco, CA Doing business as GBT
- UEI
- H4LLV5LPHA37
- CAGE
- 75SU5
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 181 Oyster Point Blvd, South San Francisco, CA 94080, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | -$10,417 |
| FY2023 | $103,988 |
Contract vehicles
Contract awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Astellas Pharma US, Inc. | Northbrook, IL | 325412 Pharmaceutical Preparation Manufacturing |
| Sobi, Inc. | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Day One Biopharmaceuticals, Inc. | Brisbane, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Acer Therapeutics Inc. | Boston, MA | 456110 Pharmacies and Drug Retailers |
| Union Hospital Inc. | Terre Haute, IN | 622110 General Medical and Surgical Hospitals |
About the company
Global Blood Therapeutics, Inc. (GBT) is a for-profit manufacturer that provides pharmaceuticals and drugs to federal agencies. GBT is a subsidiary of Pfizer Inc. and registered in SAM to receive federal awards.
GBT has provided the medication OXBRYTA to treat sickle cell disease through delivery orders totaling $177,907 issued by the Department of Justice's Bureau of Prisons Federal Correctional Complex Terre Haute. The delivery orders were awarded against GBT's Federal Supply Schedule contract for Pharmaceuticals and Drugs. GBT fulfilled the orders as the prime contractor out of South San Francisco, California.
GBT also holds a Federal Supply Schedule contract with the Department of Veterans Affairs under the Pharmaceuticals and Drugs schedule. This contract has received no orders to date but allows agencies to procure OXBRYTA from GBT through December 2023. Additionally, GBT previously held an interim Federal Supply Schedule agreement with the VA to provide OXBRYTA. No set-asides were applied to GBT's schedule contracts or associated delivery orders.
Quick answers
Is Global Blood Therapeutics, Inc. registered in SAM.gov?
Yes. Global Blood Therapeutics, Inc.'s SAM.gov registration is active through January 7, 2027.
Which contract vehicles does Global Blood Therapeutics, Inc. hold?
Global Blood Therapeutics, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Global Blood Therapeutics, Inc. received in federal contracts?
Federal contracts obligated $93,571 to Global Blood Therapeutics, Inc. in fiscal years 2023 through 2027.
What is Global Blood Therapeutics, Inc.'s most recent federal award?
Global Blood Therapeutics, Inc.'s most recent federal contract award is Oxbryta medication (15B41823F00000070), from Federal Correctional Complex Terre Haute (BOP), on March 14, 2023.
On GovTribe
See Global Blood Therapeutics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors